 Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 AMT-101 was well-tolerated Planned Phase 1b trial for the companys second clinical asset, AMT-126, in UC patients Exploring strategic partnership options to advance AMT-101 into Phase 3 in patients with chronic pouchitis Strong cash ... The post Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with M... 